SchizophreniaPAFIP_TLRNCT02897167
Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients
An observational study of Schizophrenia and Mental Disorders, run by Fundación Marques de Valdecilla at 1 site in Spain.
Trial summary
The study of immune pathways involved in the etiopathogeny of schizophrenia would be an important advance to understand the mechanisms involved in the development of this disease and it would be a turning point in drug therapy. Read more about this study
- Who is it for?
- Ages 15 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Schizophrenia, Mental Disorders, Psychotic Disorders
- What is being tested?
- Retrospective study of frozen samples and Prospective study of fresh samples
- How many people
- 150 participants
- Where
- 1 siteSpain
- Study dates
- Aug 2016to Mar 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 50 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Individuals included in the First Episode Psychosis Clinical Program (PAFIP) at the University Hospital Marqués de Valdecilla (Santander - Cantabria, Spain) between June 2011 and September 2017.
Who may be able to join
- Patients included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and September 2017.
- Living in the catchment area.
- Experiencing their first episode of psychosis before 40 years.
- Meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for a principal diagnosis of schizophreniform, schizophrenia, schizoaffective, brief reactive psychosis, or psychosis non otherwise specified.
- No prior treatment with antipsychotic medication or, if previously treated, a total life time of adequate antipsychotic treatment of less than 6 weeks.
Who cannot join
- Meeting DSM-V criteria for drug dependence.
- Meeting DSM-V criteria for mental retardation.
- Having a history of neurological disease or head injury.
Trial locations and contacts
1 site in 1 country.
Spain1 site
University Hospital Marqués de Valdecilla
Santander, Cantabria, 39008
About this study
Official title: Retrospective and Prospective Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Patients With Schizophrenia: a Comparative Effect of Risperidone vs Aripiprazole
The study of immune pathways involved in the etiopathogeny of schizophrenia would be an important advance to understand the mechanisms involved in the development of this disease and it would be a turning point in drug therapy. Until now, the mechanism of action of antipsychotics focused on the blockade or modulation of brain dopaminergic pathways. If immunological pathways responsible for neuroinflammation and neurodegeneration which involve alterations in different areas and brain pathways (including dopaminergic pathways) are discovered, investigators could develop new treatments that act on these new targets, allowing to delay the onset of the first psychotic episode and improve the evolution and impact of this disease.
Read the detailed description
Schizophrenia is a mental illness that affects approximately 1% of the population. It supposes an important impact on patients and the socio-health system, since most patients will have difficulty to have an autonomous and independent life and they will need health, economic and social resources for lifetime.
Until recently, the etiopathogeny of schizophrenia was explained by the combination of genetic and environmental factors. However, in recent years there are increasing evidence of the involvement of the immune system in the development and evolution of schizophrenia in at least a subset of patients. Although several meta-analyzes have been published where the increases or decreases in some interleukins and other proinflammatory molecules are described, immune pathways involved in the development and evolution of schizophrenia are still unknown.
The first observations that relate the immune system disorders with the development of non-affective psychosis were made a century ago where it is described the association between pathogen infections (viruses, protozoa or spirochetes) and the occurence of psychosis. Pathogens can directly affect neurons and brain structures, increasing the release of free radicals of oxygen and nitrogen or indirectly altering the activation of the innate or adaptive immune system. They have been published current epidemiological studies that support this theory and they argue that there is an increased risk of having a psychotic decompensation after hospitalization. Furthermore, it is known that many of the genes involved in schizophrenia match those genes involved in the defense against pathogens attack.
Several epidemiological studies have objectified the association of autoimmune diseases and/or chronic inflammatory diseases (intestinal, vasculitis, etc.) with some mental disorders such as schizophrenia, being stress one of the most important triggers factors in the development of both pathologies. Considering that in most cases the onset of autoimmune disease or chronic inflammatory precedes the first psychotic episode, it is hypothesized the autoimmune reaction as a trigger for psychotic symptoms. However, although these studies show statistically significant the involvement of some interleukins (increase in interleukin 6 (IL-6) mainly) in the development or exacerbation of schizophrenia, the levels of interleukins can be altered by other causes such as cardiovascular diseases, obesity and metabolic syndrome; conditions highly prevalent in patients with schizophrenia.
The innate immune system consists of various immune cells (macrophages, mast cells, dendritic cells, microglia, leukocyte, etc.) that recognize pathogen-associated molecular patterns (PAMPs) or damage-associated molecular pattern molecules (DAMPs) through a receptorial system called pattern-recognition receptors (PRRs), located on the cell surface or in cytoplasm. Toll-like receptors (TLRs) are one of the most important families of PRRs. They are transmembrane proteins that have an extracellular domain which binds to the ligands and other intracellular domain which binds to other protein complexes to initiate intracellular transduction pathways. Among the 11 known, the TLRs most studied in schizophrenia has been the TLR-4. Multiple studies have objectified that TLRs are expressed during neurodevelopment in early stages of life and they also have an important role in neurodevelopment and neuronal plasticity during adulthood. Microglia are phagocytic cells located in the central nervous system (CNS) and it is known that they express various types of TLRs. Its role as regulatory cells of CNS is done via intracellular signaling pathways that initiate TLRs. Depending the activated signaling routes, microglia perform different functions: involved positively in the immune response, in neurodevelopmental, in neuronal plasticity and in synaptogenesis, or otherwise through production of proinflammatory cytokines and free radicals of oxygen and nitrogen that favors both neuroinflammation and cerebral neurotoxicity.
Some epidemiological and experimental studies in both animals and humans suggest that infections by viruses, bacteria and protozoa in the prenatal phase (especially in the first quarter) represent a major risk factor for prenatal inflammation, abnormalities in neurodevelopment, obstetric complications and behavioral changes similar to those observed in schizophrenia patients. TLRs can cause neuronal damage in the fetus through two intracellular signaling pathways: increasing cytokine production and/or antimicrobial factors and producing a maintained activation of microglia. Both increased cytokines and antimicrobial factors such as maintained activation of microglia will cause the accumulation of free radicals of oxygen and nitrogen, resulting in neurodegeneration, necrosis and/or apoptosis, which will lead to changes both in the structure and brain function, and in the normal process of child neurodevelopment. It is known that excessive activation of microglia may lead to a reduction in the synapses between glutaminergic neurons in some brain areas such as cerebral cortex, hippocampus and basal ganglia, similar to glutamatergic hypofunction found in brains of schizophrenia patients. In addition, several studies have been published demonstrating the anti-inflammatory and antioxidant properties of antipsychotics, suggesting that its effectiveness is not only due to its action on dopaminergic receptors (classical theory) but they also have a modulatory effect on the immune system.
- Conditions
- Schizophrenia, Mental Disorders, Psychotic Disorders
- Being tested
- Retrospective study of frozen samples, Prospective study of fresh samples
- Keywords
- Psychosis, Antipsychotic Agents, Immunology, Schizophrenia Spectrum and Other Psychotic Disorders
- Medical subject headings
- Schizophrenia, Mental Disorders, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Retrospective study of frozen samplesGenetic
Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.
Prospective study of fresh samplesGenetic
Samples of serum and cells will be drawn.
| Study group | Role | What they receive |
|---|---|---|
| PAFIP patients (1) | Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and February 2016.
Retrospective study of frozen samples: samples at baseline and 3 months will be analyzed. Receives: Genetic: Retrospective study of frozen samples | |
| PAFIP patients (2) | Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between September 2016 and September 2017.
Prospective study of fresh samples: samples at baseline and 3 months will be analyzed. Receives: Genetic: Prospective study of fresh samples | |
| Controls | Healthy subjects without psychotic disorder. Receives: Genetic: Retrospective study of frozen samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measure the expression of proinflammatory molecules of activation pathways of TLRs in patients and controls using the Luminex xMAP technology: a comparative effect of Risperidone vs Aripiprazole.
The Milliplex Human High Sensitivity T Cell Magnetic Bead Kit will be used to analyze the proinflammatory molecules. This kit includes response cytokines (Th1, Th2, Th17 and regulatory) and cytokines secreted by macrophage cells and myeloid lineage. It allows a balance of pro and anti-inflammatory cytokines.
Luminex is an automated flow cytometer with an open technology that allows various tests to measure different biological parameters, reducing time, handling and cost overruns compared to more traditional methods such as Western Blot, enzyme-linked immunosorbent assay (ELISA) or traditional protein arrays. The methodology uses tests in the microsphere surface or magnetic beads of 5.6 um diameter which emit fluorescence and it is detected in a compact analyzer (Luminex).
Measured: 3 months
Secondary outcomes (2)
Assessment the expression of genes encoding proinflammatory pathways of TLRs in patients and controls using the Luminex xMAP technology.
The Mitogen-Activated and Stress-Activated Protein Kinase (MAPK/SAPK) Signaling Magnetic Bead Kit will be used to detect changes in the lysates of frozen cells of the following proteins: phosphorylated Extracellular Signal-Regulated Kinase (ERK)/MAPK 1/2 (Thr185/Tyr187), STAT1 (Tyr701), Jun Amino-terminal Kinases (JNK) (Thr183/Tyr185), Mitogen-activated protein Kinase kinase 1 (MEK1) (Ser217/221), Mitogen- and Stress-activated protein Kinase 1 (MSK1) (Ser212), Activating Transcription Factor-2 (ATF2) (Thr71), p53 (Ser15), HSP27 (Ser78), c-Jun (Ser73) and p38 (Thr180/Tyr182). This method is a fast and very useful alternative and it is more objective than the Western Blot and conventional immunoprecipitation.
Measured: 3 months
Measure the functionality of proinflammatory pathways of TLRs in patients and controls after direct cell stimulation.
Cells respond to stimuli from the microenvironment by activation of intracellular signaling cascades. Many of these stimuli are transmitted via receptors having in their intracellular domain tyrosine kinases which promote cell metabolism and his growth. Many of these signals activate Ser / Thr kinases signals, whose intermediaries are p70 S6 kinase, MSK1, Signal Transducers and Activators of Transcription (STATs) and Cyclic adenosine monophosphate Response Element-Binding protein (CREB). On the other hand, the danger signals and cell death can promote other signaling pathways such as p38, JNK and p53.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Sep 2016 (estimated)
- Study startAug 2016
- Primary completionDec 2018
- Study completionMar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fundación Marques de Valdecilla
- Sponsor type
- University, hospital or other
- Collaborators
- Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Investigación Marqués de Valdecilla
- Responsible party
- Principal investigator, Benedicto Crespo-Facorro, Fundación Marques de Valdecilla
- Investigators
- Benedicto Crespo-Facorro, Professor, Principal investigator, University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain. CIBERSAM Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02897167
- Sponsor's protocol ID
- PAFIP_TLR
- Acronym
- PAFIP_TLR
- Status last verified
- Mar 2019
- First submitted
- 7 Sep 2016
- Last updated
- 17 Feb 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pardo-de-Santayana G, Juncal-Ruiz M, Vazquez-Bourgon J, Riesco-Davila L, Ortiz-Garcia de la Foz V, Pelayo-Teran JM, Lopez-Hoyos M, Crespo-Facorro B. Active psychosis and pro-inflammatory cytokines in first-episode of psychosis. J Psychiatr Res. 2021 Feb;134:150-157. doi: 10.1016/j.jpsychires.2020.12.060. Epub 2020 Dec 22.
PubMed 33385633
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retrospective and Prospective Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Patients With Schizophrenia: a Comparative Effect of Risperidone vs Aripiprazole
- ClinicalTrials.gov ID
- NCT02897167
- Acronym / sponsor ID
- PAFIP_TLR / PAFIP_TLR
- Conditions
- Schizophrenia, Mental Disorders, Psychotic Disorders
- Keywords
- Psychosis, Antipsychotic Agents, Immunology, Schizophrenia Spectrum and Other Psychotic Disorders
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Fundación Marques de ValdecillaUniversity, hospital or other
- Collaborators
- Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Investigación Marqués de Valdecilla
- Study start
- Aug 2016 (actual)
- Primary completion
- Dec 2018 (actual)
- Study completion
- Mar 2019 (actual)
- First posted
- 13 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study of immune pathways involved in the etiopathogeny of schizophrenia would be an important advance to understand the mechanisms involved in the development of this disease and it would be a turning point in drug therapy. Until now, the mechanism of action of antipsychotics focused on the blockade or modulation of brain dopaminergic pathways. If immunological pathways responsible for neuroinflammation and neurodegeneration which involve alterations in different areas and brain pathways (including dopaminergic pathways) are discovered, investigators could develop new treatments that act on these new targets, allowing to delay the onset of the first psychotic episode and improve the evolution and impact of this disease.
Detailed description
Schizophrenia is a mental illness that affects approximately 1% of the population. It supposes an important impact on patients and the socio-health system, since most patients will have difficulty to have an autonomous and independent life and they will need health, economic and social resources for lifetime.
Until recently, the etiopathogeny of schizophrenia was explained by the combination of genetic and environmental factors. However, in recent years there are increasing evidence of the involvement of the immune system in the development and evolution of schizophrenia in at least a subset of patients. Although several meta-analyzes have been published where the increases or decreases in some interleukins and other proinflammatory molecules are described, immune pathways involved in the development and evolution of schizophrenia are still unknown.
The first observations that relate the immune system disorders with the development of non-affective psychosis were made a century ago where it is described the association between pathogen infections (viruses, protozoa or spirochetes) and the occurence of psychosis. Pathogens can directly affect neurons and brain structures, increasing the release of free radicals of oxygen and nitrogen or indirectly altering the activation of the innate or adaptive immune system. They have been published current epidemiological studies that support this theory and they argue that there is an increased risk of having a psychotic decompensation after hospitalization. Furthermore, it is known that many of the genes involved in schizophrenia match those genes involved in the defense against pathogens attack.
Several epidemiological studies have objectified the association of autoimmune diseases and/or chronic inflammatory diseases (intestinal, vasculitis, etc.) with some mental disorders such as schizophrenia, being stress one of the most important triggers factors in the development of both pathologies. Considering that in most cases the onset of autoimmune disease or chronic inflammatory precedes the first psychotic episode, it is hypothesized the autoimmune reaction as a trigger for psychotic symptoms. However, although these studies show statistically significant the involvement of some interleukins (increase in interleukin 6 (IL-6) mainly) in the development or exacerbation of schizophrenia, the levels of interleukins can be altered by other causes such as cardiovascular diseases, obesity and metabolic syndrome; conditions highly prevalent in patients with schizophrenia.
The innate immune system consists of various immune cells (macrophages, mast cells, dendritic cells, microglia, leukocyte, etc.) that recognize pathogen-associated molecular patterns (PAMPs) or damage-associated molecular pattern molecules (DAMPs) through a receptorial system called pattern-recognition receptors (PRRs), located on the cell surface or in cytoplasm. Toll-like receptors (TLRs) are one of the most important families of PRRs. They are transmembrane proteins that have an extracellular domain which binds to the ligands and other intracellular domain which binds to other protein complexes to initiate intracellular transduction pathways. Among the 11 known, the TLRs most studied in schizophrenia has been the TLR-4. Multiple studies have objectified that TLRs are expressed during neurodevelopment in early stages of life and they also have an important role in neurodevelopment and neuronal plasticity during adulthood. Microglia are phagocytic cells located in the central nervous system (CNS) and it is known that they express various types of TLRs. Its role as regulatory cells of CNS is done via intracellular signaling pathways that initiate TLRs. Depending the activated signaling routes, microglia perform different functions: involved positively in the immune response, in neurodevelopmental, in neuronal plasticity and in synaptogenesis, or otherwise through production of proinflammatory cytokines and free radicals of oxygen and nitrogen that favors both neuroinflammation and cerebral neurotoxicity.
Some epidemiological and experimental studies in both animals and humans suggest that infections by viruses, bacteria and protozoa in the prenatal phase (especially in the first quarter) represent a major risk factor for prenatal inflammation, abnormalities in neurodevelopment, obstetric complications and behavioral changes similar to those observed in schizophrenia patients. TLRs can cause neuronal damage in the fetus through two intracellular signaling pathways: increasing cytokine production and/or antimicrobial factors and producing a maintained activation of microglia. Both increased cytokines and antimicrobial factors such as maintained activation of microglia will cause the accumulation of free radicals of oxygen and nitrogen, resulting in neurodegeneration, necrosis and/or apoptosis, which will lead to changes both in the structure and brain function, and in the normal process of child neurodevelopment. It is known that excessive activation of microglia may lead to a reduction in the synapses between glutaminergic neurons in some brain areas such as cerebral cortex, hippocampus and basal ganglia, similar to glutamatergic hypofunction found in brains of schizophrenia patients. In addition, several studies have been published demonstrating the anti-inflammatory and antioxidant properties of antipsychotics, suggesting that its effectiveness is not only due to its action on dopaminergic receptors (classical theory) but they also have a modulatory effect on the immune system.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| PAFIP patients (1) | – | Genetic: Retrospective study of frozen samplesIndividuals included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and February 2016. Retrospective study of frozen samples: samples at baseline and 3 months will be analyzed. |
| PAFIP patients (2) | – | Genetic: Prospective study of fresh samplesIndividuals included in the First Episode Psychosis Clinical Program (PAFIP) between September 2016 and September 2017. Prospective study of fresh samples: samples at baseline and 3 months will be analyzed. |
| Controls | – | Genetic: Retrospective study of frozen samplesHealthy subjects without psychotic disorder. |
Who may qualify
- Ages
- 15 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Individuals included in the First Episode Psychosis Clinical Program (PAFIP) at the University Hospital Marqués de Valdecilla (Santander - Cantabria, Spain) between June 2011 and September 2017.
Key inclusion criteria (5 listed)
- Patients included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and September 2017.
- Living in the catchment area.
- Experiencing their first episode of psychosis before 40 years.
- Meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for a principal diagnosis of schizophreniform, schizophrenia, schizoaffective, brief reactive psychosis, or psychosis non otherwise specified.
- No prior treatment with antipsychotic medication or, if previously treated, a total life time of adequate antipsychotic treatment of less than 6 weeks.
Key exclusion criteria (3 listed)
- Meeting DSM-V criteria for drug dependence.
- Meeting DSM-V criteria for mental retardation.
- Having a history of neurological disease or head injury.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Retrospective study of frozen samplesFrozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected. | Genetic | Controls, PAFIP patients (1) |
| Prospective study of fresh samplesSamples of serum and cells will be drawn. | Genetic | PAFIP patients (2) |
Primary outcome
Measure the expression of proinflammatory molecules of activation pathways of TLRs in patients and controls using the Luminex xMAP technology: a comparative effect of Risperidone vs Aripiprazole.
Time frame: 3 months
The Milliplex Human High Sensitivity T Cell Magnetic Bead Kit will be used to analyze the proinflammatory molecules. This kit includes response cytokines (Th1, Th2, Th17 and regulatory) and cytokines secreted by macrophage cells and myeloid lineage. It allows a balance of pro and anti-inflammatory cytokines. Luminex is an automated flow cytometer with an open technology that allows various tests to measure different biological parameters, reducing time, handling and cost overruns compared to more traditional methods such as Western Blot, enzyme-linked immunosorbent assay (ELISA) or traditional protein arrays. The methodology uses tests in the microsphere surface or magnetic beads of 5.6 um diameter which emit fluorescence and it is detected in a compact analyzer (Luminex).
2 secondary outcomes
Assessment the expression of genes encoding proinflammatory pathways of TLRs in patients and controls using the Luminex xMAP technology.
Time frame: 3 months
Measure the functionality of proinflammatory pathways of TLRs in patients and controls after direct cell stimulation.
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2020.
- Derived from this study: PubMed 33385633Pardo-de-Santayana G, Juncal-Ruiz M, Vazquez-Bourgon J, Riesco-Davila L, Ortiz-Garcia de la Foz V, Pelayo-Teran JM, Lopez-Hoyos M, Crespo-Facorro B. Active psychosis and pro-inflammatory cytokines in first-episode of psychosis. J Psychiatr Res. 2021 Feb;134:150-157. doi: 10.1016/j.jpsychires.2020.12.060. Epub 2020 Dec 22.
- Individual participant dataSharing planned: No
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
Treatment Resistant Disorders
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benedicto Crespo-Facorro, Professor principal investigator
University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain. CIBERSAM Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Schizophrenia and Mental Disorders, run by Fundación Marques de Valdecilla at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measure the expression of proinflammatory molecules of activation pathways of TLRs in patients and controls using the Luminex xMAP technology: a comparative effect of Risperidone vs Aripiprazole. (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02897167, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2020.